QMS Medical Allied Services markets, distributes, and develops medical devices while operating patient-support programs, healthcare camps, digital health platforms, and medical education services. Its portfolio spans 900-plus SKUs, owned Q-Devices products, QMSMEDS e-commerce, point-of-care diagnostics, and healthcare services delivered through pharmaceutical and institutional relationships across India. The company is separating and consolidating its services businesses with HCAH’s PSP division under Saarathi Healthcare, creating a proposed focused entity with more than 160 programs, 1.2 million patients impacted, 2,000-plus professionals, and coverage across 35-plus cities. Management is targeting approximately Rs. 180 crore revenue for the combined services entity in FY27 versus Rs. 109 crore in FY26. QMS Medical Allied Services is shifting beyond distribution through the proposed 100% acquisition of BeamOptics Scientific. The transaction could combine BeamOptics’ seven filed patents, device engineering, CDSCO capabilities, and manufacturing with QMS’s nationwide sales network, potentially improving control over product development, supply chains, and value capture. Revenue grew 20% year-on-year to Rs. 109.4 crore in H1 FY27, but EBITDA increased only 11% and PAT declined 5%. Q2 performance was weaker sequentially, with revenue falling 8%, EBITDA margin contracting to 12.4%, and PAT declining 32% year-on-year, reflecting higher employee, finance, and depreciation costs. The balance sheet shows rising working-capital intensity and leverage. September 2026 trade receivables reached Rs. 71.9 crore, short-term borrowings rose to Rs. 81.2 crore, operating cash flow was only Rs. 4 crore for H1 FY27, and closing cash remained approximately Rs. 1 crore, limiting financial flexibility during expansion and integration.